Switch to Advanced for indicator panels, raw grades, provenance, drawing tools, and full technical tables.
$MRK
Merck & Company, Inc.
Merck & Company, Inc. is
a mega-cap
Pharmaceuticals: Major company in the Health Technology sector with a market cap of
$357B.
Health TechnologyPharmaceuticals: MajorstockStage 2 · AdvancingBase 1
$144.71latest close
⚠ Risk Signals
Head & Shoulders TopNeckline ~154.43 has broken. Measured-move risk extends toward ~151.94; a fast reclaim of 154.43 would be a failed breakdown (often bullish).
Bearish structure on the daily chart — a heads-up for anyone holding, not a short signal. Does not affect the bullish setup score.
Price bars, sourced event fields, and benchmark math only. This can adjust displayed short-term conviction; it does not change the stored scanner score or readiness.
Generic technical analysis generated mechanically from price & volume — educational research only, not financial advice or a personalized recommendation. Levels are illustrative; confirm on your own chart. New to these terms? →
Legend Verdicts6 methodology checks
Who would consider this setup, why it qualifies, and what blocks it — calculated from the same deterministic methodology rules used across Legend AI.
Council consensus:
5 of 6 legends are Watching — building, not yet a confirmed buy.
Fundamentals & leadership quality — Minervini’s published criteria · 3/7 met
C
3/7 criteria
Separate score from the Minervini Trend Template (8/8): the Trend Template grades the price structure, this grades the company & leadership (earnings, sales, margins, RS rank). A stock can ride a clean trend while its fundamentals lag, so the two often differ by design — they are not the same checklist.
O'Neil D · Avoid — The deterministic methodology check is Avoid; wait until the blocking criteria are resolved.
Pivot
Pro level
Published-method rule: Use the proper base pivot or handle high after CANSLIM leadership and market-direction checks are satisfied. Evidence: Canonical setup geometry is available with Pro.
Entry trigger
Pro level
Published-method rule: Require a breakout through the pivot on volume at least 40% above average; the valid buy zone ends 5% above the pivot. Evidence: Canonical setup geometry is available with Pro.
Initial stop
Pro level
Published-method rule: Use the setup's structural stop with a hard 7–8% maximum-loss ceiling from the actual entry. Evidence: Canonical setup geometry is available with Pro.
Trail
Rule-based
Published-method rule: Protect progress under constructive support such as the 21-day or 10-week line; a stop may ratchet higher but never lower. Evidence: Planned management rule; no stored stop or broker order is changed automatically.
Exit / invalidation
Pro level
Published-method rule: Exit on the hard loss limit, a decisive support break, or a rule-based climax/distribution signal; a normal 20–25% advance is reviewed rather than assumed permanent. Evidence: Canonical setup geometry is available with Pro.
Deterministic educational plan, not a recommendation. No order or stop is changed automatically. Method and sources →
Grades the price structure — moving-average stacking, distance from the 52-week high/low, and relative strength above the ≥70 uptrend bar. This is the technical trend check; the company's fundamentals and ≥80 RS leadership are scored separately in the Grade Card.
✓
Price above SMA 150 & 200$144.71 vs SMA150 $123.70 / SMA200 $119.18
✓
SMA 150 above SMA 200SMA150 $123.70 vs SMA200 $119.18
✓
SMA 200 trending upSlope +5.84 over 20 days
✓
SMA 50 above SMA 150 & 200SMA50 $135.67
✓
Price above SMA 50$144.71 vs SMA50 $135.67
✓
30%+ above 52-week low+86.5% from $77.58
✓
Within 25% of 52-week high-7.8% from $156.92
✓
RS score above 70RS 83
Fundamentals
52W Range
85%
Mkt Cap SEC
357.0B
Rev YoY
+1%
EPS TTM
$7.28
P/E TTM
19.9x
Float
2.5B
Company
Company profile
Merck & Company, Inc.
MRK · NYSE
· Health Technology
· Pharmaceuticals: Major